ofatumumab

CHEBI:CHEBI_753814

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

generic_name
ofatumumab
rxcui
1658048
product_type
HUMAN PRESCRIPTION DRUG
listing_expiration_date
20251231
dosage_form
INJECTION, SOLUTION
route
INTRAVENOUS
active_ingredient_strength
20 mg/mL
marketing_category
BLA
labeler_name
Novartis Pharmaceuticals Corporation
manufacturer_name
Novartis Pharmaceuticals Corporation
marketing_start_date
20160201
package_marketing_start_date
20160201
nui
N0000175657
pharm_class_epc
CD20-directed Cytolytic Antibody [EPC]
pharm_class
CD20-directed Antibody Interactions [MoA]
pharm_class_moa
CD20-directed Antibody Interactions [MoA]
brand_name
ARZERRA
brand_name_base
ARZERRA
product_ndc
0078-0690
application_number
BLA125326
spl_id
eeb96642-025c-4cc3-af54-b8859ac86a61
active_ingredient_name
OFATUMUMAB
package_ndc
0078-0690-61
package_description
50 mL in 1 VIAL, SINGLE-USE (0078-0690-61)
unii
M95KG522R0
spl_set_id
77785ce3-e8df-4ca1-8f8e-6c418c6a17de
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class